Mary Matyskiela

Mary Matyskiela, Ph.D. is Vice President of Molecular Sciences at Neomorph and brings more than 20 years of experience in the ubiquitin-proteasome field. Mary received her B.S. in Chemistry from Yale University, where she performed undergraduate research in the lab of Dr. Craig Crews. She then moved to the University of California San Francisco for graduate work on ubiquitin ligase mechanism in the lab of Dr. David Morgan. She went on to perform postdoctoral research at the University of California Berkeley, studying the structure and function of the 26S proteasome with Dr. Andreas Martin, HHMI. Following her academic training, she moved to Celgene and Bristol Myers Squibb, where she spent 6 years working in targeted protein degradation drug discovery, most recently as Associate Director of Structural Biology and Proteomics, Oncology West. Mary is known for her work in elucidating the molecular mechanisms and expanding the horizons of molecular glue targeting through cereblon-CRL4, and is an author of foundational publications in the molecular glue field.